SCHEMBL5535635

SCHEMBL5535635

F[CH]c1cccc(-c2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.44
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
ALDH1A1 P00352 2/20 0.43
BCL2L1 Q07817 1/20 0.41
BAD Q92934 1/20 0.41
NFE2L2 Q16236 1/20 0.40
MGLL Q99685 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
KMO O15229 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
MAPK1 P28482 1/20 0.39
ALOX5 P09917 1/20 0.38
KCNH2 Q12809 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28315999 0.83 ESR1 (0.61) TRIM24TRIM33BCL2L1HDAC2HDAC8
SCHEMBL2843934 0.80 MAOA (0.48) MAOATRIM24TRIM33ALDH1A1BCL2L1
SCHEMBL28316018 0.78 ABL1 (0.58) NFE2L2HDAC4HDAC2HDAC8MAPK1
SCHEMBL7535716 0.78 NFE2L2 (0.58) MAOABCL2L1BADNFE2L2HDAC2
SCHEMBL530889 0.78 NFE2L2 (0.58) MAOABCL2L1BADNFE2L2HDAC2
SCHEMBL5158829 0.76 MAOA (0.44) MAOATRIM24TRIM33ALDH1A1BCL2L1
SCHEMBL1005178 0.76 MAOA (0.44) MAOATRIM24TRIM33ALDH1A1BCL2L1
SCHEMBL8192988 0.76 MAOA (0.44) MAOATRIM24TRIM33ALDH1A1BCL2L1
SCHEMBL97618 0.76 TRIM24 (0.69) MAOATRIM24TRIM33ALDH1A1CA12
SCHEMBL30618844 0.76 ALDH1A1 (0.59) MAOATRIM24TRIM33ALDH1A1BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOA 2885/4885TRIM24 3805/4885TRIM33 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.